Dr. Jitendra Singh at RSSDI: India a Global Diabetes Research Hub
Synopsis
Key Takeaways
India's genetic diversity — long a clinical challenge — is now its most powerful scientific asset. Union Science and Technology Minister Dr. Jitendra Singh made that case forcefully on Friday, 20 November 2026, delivering the inaugural address at the four-day Annual Conference of the Research Society for Study of Diabetes in India (RSSDI) in Bengaluru, laying out a sweeping vision for how the country can lead the world in diabetes and precision medicine research.
India's genetic edge — from liability to laboratory advantage
At the heart of Dr. Singh's address was a reframing: India's enormous, genetically diverse population is not simply a country with a large diabetes burden — it is a living dataset of unmatched scientific value. 'India's vast population and genetic diversity offer a unique opportunity to develop scientific insights and healthcare solutions with relevance not only for the country, but for the entire mankind,' the minister stated. That framing — local scale, global payoff — has become a consistent thread in how the Ministry of Science and Technology now pitches India's role in precision medicine.
The country's non-communicable disease challenge is real and urgent. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), launched in 2010, acknowledged the rising tide of metabolic disorders. What has shifted in the years since is the nature of the scientific response — moving from epidemiological surveillance toward molecular and genetic intervention design, powered by significantly expanded Department of Biotechnology (DBT) funding.
Over a dozen DBT projects — from gut microbiome to engineered bacteria
Dr. Singh enumerated more than a dozen active diabetes-related research projects running under the Ministry, most channelled through the DBT. The range is striking. An Indo-Danish Gut Microbiome Study — a bilateral collaboration with Denmark — is probing the relationship between gut microbial profiles and Type 2 Diabetes Mellitus. A separate DBT-backed project is investigating genetically engineered E. coli capable of producing GLP-1, the hormone-mimicking pathway that has driven the global blockbuster class of obesity and diabetes drugs.
Other studies in the pipeline target different points on the disease arc. One project is examining whether preconception-to-early-childhood interventions can reduce cardiometabolic risks — including childhood blood glucose, blood pressure and adiposity. Another is building a biomarker framework to predict Type 2 Diabetes in women with a history of gestational diabetes, a cohort at disproportionately high subsequent risk. A fifth study is mapping the link between Type 2 Diabetes and Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD), a comorbidity increasingly central to metabolic medicine globally.
Prevention as a national duty — not just a doctor's directive
Perhaps the most politically charged line of Dr. Singh's address was his insistence that diabetes prevention is 'a national responsibility, not merely a doctor's obligation.' He invoked Prime Minister Narendra Modi directly — noting that PM Modi has repeatedly pressed this point — to signal that the prevention agenda carries the highest political endorsement and demands cross-sectoral mobilisation beyond the health fraternity alone.
That framing matters. It signals an intent to bring youth-focused metabolic health interventions into the orbit of science, education and social policy — not just clinical practice. India's youth demographics make the stakes clear: a generation entering adulthood with elevated cardiometabolic risk could translate into an economic and social burden that dwarfs today's numbers.
With a ministerial mandate, bilateral scientific partnerships, and a clutch of frontier research projects now underway, India's answer to the global diabetes crisis may be taking shape in its own laboratories — and the world will be watching what that data yields.